Hamaguchi Reo, Narui Ryoko, Morikawa Hiromasa, Wada Hiromi
Japanese Society on Inflammation and Metabolism in Cancer, Kyoto, Japan.
Cancer Diagn Progn. 2021 Jul 3;1(3):157-163. doi: 10.21873/cdp.10021. eCollection 2021 Jul-Aug.
BACKGROUND/AIM: This study aimed to investigate the effects of the combination of alkalization therapy (an alkaline diet and bicarbonate therapy) and intravenous vitamin C treatment on chemotherapy outcomes in patients with small-cell lung cancer (SCLC) (study registration: UMIN000043056).
Twelve patients with SCLC in the intervention group (receiving both alkalization therapy and vitamin C treatment together with chemotherapy) were retrospectively compared to 15 patients with SCLC in the control group (receiving chemotherapy only).
The mean urine pH of the intervention group was significantly higher than that of the control group (7.32±0.45 vs. 6.44±0.74, respectively; p<0.005). The median overall survival for the intervention group was 44.2 months (95% confidence interval=22.0-not reached), as compared with 17.7 months for the control group (95% confidence intervaI=13.5-not reached; p<0.05).
The combination of alkalization therapy and intravenous vitamin C treatment may be associated with favorable outcomes in patients with SCLC receiving chemotherapy.
背景/目的:本研究旨在探讨碱化疗法(碱性饮食和碳酸氢盐疗法)与静脉注射维生素C联合治疗对小细胞肺癌(SCLC)患者化疗效果的影响(研究注册号:UMIN000043056)。
回顾性比较干预组12例SCLC患者(在接受化疗的同时接受碱化疗法和维生素C治疗)与对照组15例SCLC患者(仅接受化疗)。
干预组的平均尿液pH值显著高于对照组(分别为7.32±0.45和6.44±0.74;p<0.005)。干预组的中位总生存期为44.2个月(95%置信区间=22.0-未达到),而对照组为17.7个月(95%置信区间=13.5-未达到;p<0.05)。
碱化疗法与静脉注射维生素C联合治疗可能使接受化疗的SCLC患者获得较好的治疗效果。